FDA questions safety of rifapentine use with HIV drugs -news-.
D000995:Antitubercular Agents / Q000009:adverse effects*; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000097:blood*; D006801:Humans; D019469:Indinavir / Q000097:blood*; D012293:Rifampin / Q000009:adverse effects / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
D000995:Antitubercular Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D012293:Rifampin; C018421:rifapentine